Lucentis
OVERDOSE
Planned initial single doses of ranibizumab injection 1.0 mg were associated with clinically significant intraocular inflammation in 2 of 2 patients injected. With an escalating regimen of doses beginning with initial doses of ranibizumab injection 0.3 mg, doses as high as 2.0 mg were tolerated in 15 of 20 patients.
CONTRAINDICATIONS
Ocular or Periocular Infections
LUCENTIS is contraindicated in patients with ocular or periocular infections.
Hypersensitivity
LUCENTIS is contraindicated in patients with known hypersensitivity to ranibizumab or any of the excipients in LUCENTIS.
Generic Name: Ranibizumab Injection
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
WebMD Daily
Get breaking medical news.
Glaucoma Laser Treatment
Glaucoma is a sight-stealing condition caused by pressure in the eye. Now patients are finding results through glaucoma laser treatment. See more WebMD Videos »
Lucentis
Health Resources
2008 Election & Health Care on WebMD. Get Informed.
Updated & New
RxList does not provide medical advice, diagnosis or treatment.